The Surface, Issue #6 is now available! This month we feature publications on predictors of response and drug survival, and systematic reviews of rare cutaneous disorders. The Surface was emailed to all PSOLVE+ members on Mon, Aug 2 and can be read online here.

The Surface Issue #6, August 2021 edition, was sent to all PSOLVE+ members by email on Monday, August 2, and can be accessed online here. This edition covers:

  • Predictors of methotrexate discontinuation in plaque psoriasis
  • Systematic review of predictive biomarkers for treatment response in psoriasis and psoriatic arthritis
  • Normalization of bone microarchitecture following anti-TNF treatment for PsA
  • Characterizing Degos disease by systematic review
  • Case report of cutaneous Emmonsia infection in a renal transplant recipient
  • Case report of atypical melanocytic nevi with segmental distribution

To view all issues of The Surface, go to psolve.org/the-surface

The Surface, Issue #5 is now available, highlighting 5 new articles clinically relevant for Canadian dermatologists. The Surface was emailed to all PSOLVE+ members on Mon, Jul 5 and can be read online here.

The Surface Issue #5, July 2021 edition, was sent to all PSOLVE+ members by email on Monday, July 5, and can be accessed online here. This edition covers:

  • Upadacitinib for biologic-refractory psoriatic arthritis
  • Urticaria disease activity during and after pregnancy
  • Case reports of paradoxical sarcoidosis in patients on anti-TNFs
  • Fixed drug eruption following two different antibiotics
  • Local hyperthermia treatment for cervical HPV

To view all issues of The Surface, go to psolve.org/the-surface

The Surface, Issue #4 is now available, this month highlighting 6 new articles clinically relevant for Canadian dermatologists. The Surface was emailed to all PSOLVE+ members on Tues, Jun 1 and can be read online here.

The Surface Issue #4, June edition, was sent to all PSOLVE+ members by email on Tuesday, June 1, and can be accessed online here. This edition covers:

  • Safety and efficacy of secukinumab in a single, 300mg/2mL pre-filled syringe
  • Risk of malignancy with up to five years of secukinumab treatment
  • Reviewing the evidence for over-the-counter supplements in dermatology
  • Telogen effluvium patient demographics during the pandemic
  • North American Contact Dermatitis Group patch testing with sodium disulfite
  • Hereditary angioedema in the emergency department

To view all issues of The Surface, go to psolve.org/the-surface

The Surface, Issue #3 is now available, this month highlighting 4 new articles clinically relevant for Canadian dermatologists. The Surface was emailed to all PSOLVE+ members on Tues, May 4 and can be read online here.

The Surface Issue #3, May edition, was sent to all PSOLVE+ members by email on Tuesday, May 4, and can be accessed online here. This edition covers:

  • Considerations for use of SARS-CoV-2 vaccines in psoriasis patients
  • Retrospective analysis of oral methotrexate for alopecia areata
  • Case series and literature review of pleural effusion in PsA patients
  • Polymorphisms associated with methotrexate treatment outcomes

To view all issues of The Surface, go to psolve.org/the-surface

The Surface, Issue #2 is now available! Check out this month’s summaries of recent publications with high clinical relevance to Canadian dermatologists.

The Surface Issue #2, April edition, was sent to all PSOLVE+ members by email on Monday, March 29, and can be accessed online here. This edition covers:

  • Vaccine literacy amongst patients with psoriasis
  • Pregnancy outcomes from the PSOLAR registry
  • Bimekizumab phase 3 results in moderate-to-severe plaque psoriasis
  • Targeting the IL-23/IL-17 pathway in plaque psoriasis
  • Compassionately addressing teratogenic risk factors in the transgender population
  • Real-world safety profile of acitretin in psoriasis patients

To view all issues of The Surface, go to https://psolve.org/the-surface/

Introducing “The Surface”, a monthly feature of the PSOLVE+ community where recent articles are selected and summarized for clinical relevance to Canadian dermatologists

We’re pleased to introduce a new feature for the PSOLVE+ community – The Surface!

The Surface is a monthly selection of new publications clinically relevant to the PSOLVE+ community of Canadian dermatologists.

The Surface will be sent to all PSOLVE+ members by email each month, with highlights in the weekly PSOLVE+ email digests. You can view all issues of The Surface online here.

Drs. Gordon Searles, Howard Yanofsky and Jensen Yeung discuss the role of the dermatologist in managing disease progression and optimizing biologic therapy. [Video English & French 40 min]

>> English: http://bit.ly/VidYanofskyetal [40 min]

>> Français: http://bit.ly/VidYanofskyetal_FR [41 min]


This program showcases leading dermatology experts from across Canada as they discuss the management of psoriatic disease. Providing valuable insights into the diagnosis and treatment of psoriatic disease, Dr. Gordon E. Searles (Edmonton), Dr. Howard Yanofsky (Montreal) and Dr. Jensen Yeung (Toronto) discuss the role of the dermatologist in managing disease progression and optimizing biologic therapy. This program addresses 3 important topics:

  • Part 1: From Psoriasis to Psoriatic Arthritis – Exploring the Role of the Dermatologist
  • Part 2: Understanding the EXCEED Trial for Dermatologists
  • Part 3: Treatment Strategies by Patient Profile

Ce programme présente les principaux experts canadiens en dermatologie alors qu’ils discutent de la gestion de la maladie psoriasique. Fournissant des informations précieuses sur le diagnostic et le traitement de la maladie psoriasique, le Dr Gordon E. Searles (Edmonton), le Dr Howard Yanofsky (Montréal) et le Dr Jensen Yeung (Toronto) discutent du rôle du dermatologue dans la gestion de la progression de la maladie et l’optimisation des produits biologiques. Ce programme aborde 3 sujets importants:

  • Partie 1: Du psoriasis au rhumatisme psoriasique – Explorer le rôle du dermatologue
  • Partie 2 : Comprendre l’essai EXCEED pour les dermatologues
  • Partie 3 : Stratégies thérapeutiques par profil de patient